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DLC1 (Deleted in Liver Cancer 1) gene encodes a RhoGTPase-activating protein (RhoGAP), which exerts most of its
tumor suppressor functions through suppression of small Rho GTPases proteins RhoA, RhoB, RhoC and to some
degree Cdc42, but not Rac. RhoGTPases are implicated in NF-κB activation in highly invasive prostate carcinoma (PCA),
with consequences on cell proliferation, survival and metastatic capacity. Here we demonstrate that DLC1 transduction
in two androgen-independent (AI) and highly metastatic PCA cell lines negatively regulates NF-κB activity in a
GAP- and α-catenin-dependent manner. Expressed DLC1 protein suppresses the phosphorylation of NF-κB inhibitor,
IκBα, causes its relocation from membrane ruffles into cytoplasm and attenuates its ubiquitination and subsequent
degradation. DLC1-mediated NF-kB suppression and its effects are comparable to NF-κB inhibition using either shRNA
knockdown or peptide inhibitor. Expression of transduced DLC1 suppressed the expression of NF-κB mediated genes.
Such effects were found to be reliant on presence of calcium, indicating that the observed modifications are
dependent on, and enabled by DLC-mediated stabilization of adherens junctions. These results expand the
multitude of DLC1 interactions with other genes that modulate its oncosuppressive function, and may have potential
therapeutic implications.
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Metastatic prostate cancer (PC), resistant to conventional
therapies, hormone deprivation and ablation, is one of the
leading causes of death of men in United States. In about
one third of post-prostatectomy patients, tumor cells
reappear as local or distant metastasis, develop hormone
refractoriness and acquire increasingly more aggressive
phenotype. A growing body of evidences shows that a
transcriptional factor NF-κB is constitutively activated in
primary PC (Suh et al. 2002), and plays an important role
in tumor invasion, metastasis, angiogenesis, and acquisi-
tion of chemotherapy resistance (Sweeney et al. 2004; Catz
and Johnson 2001).
Although commonly called NF-kB, it is in fact a group
of related homo- and heterodimeric transcription fac-
tors composed of five members of the Rel/NF-κB family* Correspondence: popescun@mail.nih.gov
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in any medium, provided the original work is pof proteins - RelA (p65), RelB, c-Rel, NF-kB1 {p50) and
NF-kB2 (p52) – all of which contain a conserved Rel
homology region and C– and N-terminal domains re-
sponsible for dimerization and DNA binding, respec-
tively (Hoffmann et al. 2003). Activation of NF-κB
occurs when its specific inhibitor from the Ik-B family
of proteins gets phosphorylated (and subsequently de-
graded) by either tripartite (IKKα, IKKβ, IKKγ) or ho-
modimeric (IKKα, IKKα) I-kB kinase (IKK) complex
(Ghosh and Karin 2002; Luo et al. 2005). Upon activa-
tion NF-κB relocates from cytoplasm to nucleus where,
after some additional molecular modifications, it binds
to promoter region of numerous genes involved in in-
flammatory response, cell growth, apoptosis and differ-
entiation. Increased action of IKK complex appears to
be in the root of constitutive NFκB activity in PC
(Palayoor et al. 1999; Pajonk et al. 1999), which affects
expression of genes like cyclin D1, c-myc and Bcl-2 that
drive cellular proliferation or confer resistance to apop-
totic signals. NF-κB-mediated expression of genes likean open access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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further contribute to the development of aggressive
PCA (Karin et al. 2002).
On the other side, among multiple factors implicated
in the initiation and progression of PC (Xu et al. 2002;
Albany et al. 2011; Hsieh et al. 2001) tumor suppressor
gene DLC1, a member of RhoGAP family of genes,
stands out, as it has been shown to be down-regulated
or absent not only in PC, but in various other solid tu-
mors and hematological malignancies (Guan et al. 2006;
Durkin et al. 2007; Ullmannova et al. 2009). Introduction
of DLC1 in highly metastatic PCA cells suppressed prolif-
eration, invasiveness and anchorage-independent growth
and restored response to apoptotic signaling (Guan et al.
2008). Conversely, DLC1 silencing in prostate epithelial
cells promoted pro-angiogenic responses through up-
regulation of vascular endothelial growth factor (VEGF),
accompanied by the accumulation of hypoxia-inducible
factor 1α and its nuclear localization (Shih et al. 2010).
The rationale for undertaking this study was based on
evidence showing that NF-κB is constitutively activated
in PC cells, is a major transcription factor involved in
metastasis to bone, and, importantly, DLC1expression
suppresses proliferation of PC cells in vitro, and their
growth in nude mice (Andela et al. 2003, Guan et al.
2008). We used metastatic, androgen-independent PCA
cell lines C4-2-B2 and PC-3, deficient in DLC1 expression
but with high NF-κB activity, to examine the relationship
between NF-κB and DLC1 and showed that in these cells
restoration of DLC1 expression inhibited the phosphoryl-
ation (i.e. activation) of NF-κB in the α-catenin- and GAP-
dependent manner.Results
DLC1 suppresses NF-κB activity in prostate cancer cells
When compared to normal, immortalized, DLC1-
positive prostate epithelial cell RWPE-1, metastatic PCA
cells C4-2-B2 and PC-3 showed (Figure 1A, B) lack of
DLC1 expression, higher levels of active Rho, and signifi-
cantly higher levels of NF-κB activation, as measured by
phosphorylation of p65 subunit of NF-κB. Transduction
of DLC1 into C4-2-B2 cells, and restoration of its ex-
pression to the level comparable to that in RWPE-1
(Figure 1B), reduced activation of NF-κB as demonstrated
by both p65 phosphorylation (Figure 1C) and by luciferase
reporter assay (Figure 1D). On the other hand, re-
expression of DLC1 in PC3 cells did not significantly
affect NF-κB activation (Figure 1C, D), although a DLC1
was suppressing active RhoA in both cells (Figure 1C).
Knocking down of both DLC1 and α-catenin in RWPE-1
cells suppresses the phosphorylation of p65 subunit of
NF-κB and, thus, underscores the role of DLC1 and α-
catenin in NF-κB activity (Figure 1E).DLC1-mediated suppression of NF-κB is α- catenin
dependent
Since PC3 cells, in addition to absence of DLC1 expres-
sion, also lack expression of α- catenin, which is abun-
dantly expressed in C4-2-B2 cells, we hypothesized that
α-catenin might be a “missing link” in DLC1-mediated
inhibition of NF-κB activation of PC3 cells. We, therefore,
probed extracts of C4-2-B2 and PC-3 cells with anti-
phospho-p65 antibody, to see if α-catenin status affects
p65 phosphorylation and activation of NF-κB. In both cell
lines simultaneous expression of DLC1 and α-catenin was
associated with lower levels of p65 phosphorylation, indi-
cative of reduced NF-κB activation (Figure 2A). Confocal
imunnofluorescence analysis of C4-2-B2 and PC-3 cells
(Figure 2B) also showed that presence of either DLC1 or
α-catenin did not affect the nuclear phosphorylated NFκB,
but that co-expression of DLC1 and α-catenin reduced
the amount of active NFκB below the level of detection.
NF-κB luciferase reporter gene assay (Figure 2C) provided
additional confirmation that both DLC1 and α-catenin
are required for the maximum suppression of NFκB
activation; used alone neither the full-length DLC1 nor
α-catenin were not able to produce a statistically signifi-
cant effect.
RhoGAP activity and interaction with α-catenin is required
for NF-κB down regulation
To see if DLC1-mediated inhibition of NF-κB activity
was RhoGAP-dependent, C4-2-B2 cells were either
transduced with wild-type DLC1, or transfected with
DLC1 GAP mutant R718E. In the later case, stable
clones were selected using G148. Subsequent compari-
son of NF-κB p65 subunit phosphorylation in aforemen-
tioned GAP-competent and GAP-incompetent C4-2-B2
cells showed no reduction in p65 phosphorylation and,
therefore, no inhibition of NF-κB activation in cells bear-
ing mutant GAP (Figure 3A). In addition, cells trans-
fected with DLC1 deletion mutant Δ340-435, lacking the
critical α-catenin-binding region, also were not able to
suppress the phosphorylation and activation of NF-κB
(Figure 3A). Luciferase reporter gene activation assay
confirmed these observations (Figure 3B), which, to-
gether, revealed that DLC1-mediated NF-κB regulation
depends on both the DLC1 RhoGAP activity, and on its
ability to effectively bind α-catenin.
DLC1-mediated adherens junctions stabilization is
responsible for inhibition of NF-κB activity
The integrity of adherens junctions (AJ) is affected by avail-
ability of calcium ions (Ca2+); depletion of Ca2+ disrupts
AJs as shown by E-cadherin staining of DLC1-transduced
C4-2-B2 cells, and cells with DLC1 deletion mutant
Δ340-435, lacking the critical α-catenin-binding region
(Figure 4A). Interestingly, such cells with compromised AJ
Figure 1 DLC1 suppresses NF-κB activation. (A) Relative luciferase activity of NF-κB reporter in RWPE-1, C4-2-B2 and PC-3 cells, (B) Western
blot showing the level of DLC1, pNF-κB (p65), NF-κB (p65), RhoAGTP, and total RhoA in RWPE-1, C4-2-B2 and PC-3 cells and level of DLC1 in
RWPE-1 and Ad-DLC1 transduced (50MOI) C4-2-B2 and PC-3cells. (C) Western blot showing level of phosphorylated p65 subunit of NF-κB in the
Ad-Lac Z and Ad-DLC1 transduced C4-2-B2 and PC-3 cells. (D) Relative luciferase activity of NF-κB reporter in AD-LacZ and DLC1 transduced
C4-2-B2 and PC-3 cells. All values are means ± SD of three independent counts. (E) Western blot showing the level of phosphorylated p65
subunit of NF-κB in DLC1- and α-catenin-knock down RWPE-1 cells.
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anti-pNF-κB staining in absence of Ca2+) (Figure 4B) and
confirmed by luciferase reporter assay (Figure 4C). To
examine if DLC1-mediated stabilization of AJs would re-
duce NF-κB activity by enabling its binding to AJ’s pro-
teins, primarily E-cadherin, C4-2-B2 cells transduced witheither LacZ or DLC1, were additionally transfected with
GFP E-cadherin (Figure 4D right), their respective cell ex-
tracts immunoprecipitated with anti-GFP, and those im-
munoprecipitates probed with anti-NF-κB antibodies.
When compared to DLC1-negative LacZ-transduced cells,
DLC1-positive cells exhibited increased amounts of
Figure 2 Both DLC1 and α –catenin expression are required to regulate NF-κB activity. (A) Western blot of total and phosphorylated NF-κB
from cell lysates of C4-2-B2 (transduced and/or stably transfected with Ad-LacZ, Ad-DLC1, Ad-DLC1 + sh-Neo or Ad-DLC1 + sh-α-catenin) and
PC- 3 cells (transduced with Ad-LacZ, Ad-DLC1 orAd-DLC1 + Ad-α -catenin). (B) Immunostaining of the above described transduced and stable
transfected C4-2-B2 and PC- 3 cells with anti-phospho NF-κB, anti-DLC1 and anti-α -catenin antibodies. Scale bar = 20 μm. (C) C4-2-B2, and PC-3
cells were transfected with NF-κB reporter vector and luciferase activity was measured with dual luciferase assay. All values are means ± SD of
three independent counts.
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reduced NF-κB activity. Furthermore, analysis of membrane
and cytosolic fractions of LacZ- or DLC1-transduced C4-2-B2 cells, showed a pronounced shift in NF-κB distribution
from cytosole to membrane in DLC-positive cells
(Figure 4E), indicating that DLC1-mediated stabilization
Figure 3 Suppression of NF-κB activity is GAP- and α –catenin-dependent (A) Western blot of pNF-κB (p65), NF-κB (p65) and DLC1
(V-5) expression in C4-2-B2 cells transduced with Ad-Lac Z or Ad-DLC1 and stably transfected with either DLC1 GAP-mutated (R718E)
or α -catenin binding deficient constructs (Δ340-435). (B) Dual Luciferase reporter assay for NF-κB activity in above-mentioned C4-2-B2 cells.
All values are means ± SD of three independent counts.
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activity.
DLC1 inhibits IκBα localization to membrane ruffles and
proteasomal degradation
To further explore the mechanism through which DLC1
modulates NF-κB activity, we examined phosphorylation
of NF-κB’s specific inhibitor, IκBα, a molecular modification
instrumental for the release of active NF-κB to nucleus.
As shown in Figure 5A, phosphorylation of IκBα was de-
creased in the presence of DLC1. Use of DLC1 deletion
mutant Δ340-435 caused no effect on pIkB phosphoryl-
ation, thus affirming the role of this region of DLC1 in the
signaling.Confocal microscopy analysis of IκBα cellular distribution
showed that in DLC1-negative C4-2-B2 cells the inhibitor
was localized to the membrane ruffles. Transduction and
expression of DLC1 was followed by IκBα distribution
throughout the cytoplasm but, interestingly, Ca2+ depletion
reversed that process causing IκBα to withdraw to mem-
brane again (Figure 5B). Expression of DLC1 deletion mu-
tant ΔD340-435 lacking the α-catenin-binding region, was
not able to completely relocalize IκBα to the cytoplasm,
and certain amount of IκBα remained present in the mem-
brane ruffles (Figure 5B).
Ubiquitination assay of IκBα showed that the expression
of wild-type DLC1 attenuated ubiquitination of IκBα,
whereas GAP-incompetent DLC1 mutant R718E failed to
produce such an effect (Figure 5C). Here again elimination
Figure 4 DLC1 affects NF-κB activity is dependent on AJs stability. (A) C4-2-B2 cells, transduced with Ad-DLC1 or transfected with deletion
mutant DLC1 Δ340-435 (lacking the α-catenin-binding region), were grown in media with or without calcium, and immunostained for E-cadherin
and DLC1. Scale bar = 20 μm. (B) C4-2-B2 cells transduced and stably transfected with Ad-DLC1 and sh-α -catenin were grown in media with and
without calcium for 24 hours, and stained for phospho NF-κB, DLC1 and α -catenin. Scale bar = 20 μm. (C) Luciferase reporter assay confirms
increased NF-κB activity in C4-2-B2 cells grown in calcium-negative media. (D) Cell extracts from C4-2-B2 cells transduced and stably transfected
with Ad-DLC1 + GFP (lane 1), Ad-LacZ + GFP-E-cadherin (lane 2) or Ad-DLC1 + GFP-E-Cadherin, were immunoprecipitated with anti-GFP antibodies
and western blotted with anti-NFκB-antibodies. Result of the whole cell extract is shown in the right. (E) Membrane and cytosolic fractions of
NF-κB in the LacZ and DLC1 transduced C4-2-B2 cells.
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DLC1 expression, i.e., increased the ubiquitination of
IκBα, suggesting that DLC1-mediated stabilization of AJs,
and spatial distribution of both IκBα and NF-κB are two
major factors affecting NF-κB signaling.
Colony formation, invasiveness and apoptosis of
metastatic prostate carcinoma cells are affected similarly by
DLC1-mediated NF-κB suppression, sh(p65)NF-κB silencing
or pharmacological down-regulation of NF-κB
To better understand the magnitude and the consequences
of DLC1-mediated suppression of NF-κB activation, DLC1-
negative C4-2-B2 cells were either transduced by DLC1
gene, or treated by shRNA (targeting p65 subunit of NF-
κB), or by pharmacological NF-κB peptide inhibitor. Useof sh(p65)NF-κB significantly reduced NF-κB expression
on protein level (Figure 6A) whereas use of 150 μM pep-
tide inhibitor completely abolished NF-κB transcriptional
activity. Expression of DLC1 protein reduced colony for-
mation efficiency, and invasion capability of C4-2-B2 cells,
to the levels similar to one caused by sh(p65)NF-κB or by
chemical NF-κB peptide inhibitor (Figure 6B, C). The
same pattern was observed in apoptosis assay where
DLC1 effect was comparable to the ones caused by NF-κB
inhibitors (Figure 6D). In addition, expression of several
NF-κB-inducible genes with roles in cell proliferation, in-
vasion and apoptosis - such as cyclin D1, c-Myc, Bcl-xL
and vimentin - was notably suppressed by simultaneous
co-expression of DLC1 and α-catenin, in a pattern similar
to the effect of NF-κB peptide inhibitor (Figure 6E), which,
Figure 5 DLC1 expression causes relocation and suppresses phosphorylation and ubiquitination of IκBα. (A) Western blots of phospho-IκBα
and total IκBα in Ad-LacZ-, Ad-DLC1-transduced or DLC1 deletion mutant ΔD340-435-transfected C4-2-B2 cells. (B) IκBα localization in Ad-LacZ-,
Ad-DLC1-transduced or DLC1 deletion mutant ΔD340-435-transfected C4-2-B2 cells in the presence and absence of calcium. Scale bars 20 μm
and 10 μm, respectively. (C) Ubiquitination assay of IκBα of proteasome inhibitor MG132 treated Ad-LacZ and Ad-DLC1 transduced C4-2-B2 and
DLC1R718E transduced cells in the presence and absence of calcium.
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in NF-κB- mediated signaling.
Discussion
This study demonstrates that DLC1 expression in androgen-
independent and highly metastatic PCA cells C4-2-B2 and
PC-3 with constitutive activation of NF-κB (Gasparian
et al. 2002) negatively regulates NF-κB activity in a GAP-
and α-catenin-dependent manner. DLC1 suppresses the
phosphorylation of NF-κB inhibitor, IκBα, causes its reloca-
tion from membrane ruffles, and attenuates its ubiquitina-
tion and subsequent degradation. DLC1-mediated NF-kB
suppression and its consequences were comparable to NF-
κB inhibition using either shRNA knock down or NF-κB
peptide inhibitor. In addition, DLC1 transduction sup-
pressed the expression of NF-κB mediated genes. These
effects were found to be reliant on presence of calcium,
which indicates that the observed modifications are
dependent on, and enabled by DLC1-mediated stabiliza-
tion of adherens junctions (Tripathi et al. 2012).
Constitutive activation of NF-κB pathway in prostate,
lung, liver and breast cancers (Gasparian et al. 2002;
Chiao et al. 2002; Biswas et al. 2004), correlates with the
expression of several genes involved in immune and
inflammatory responses, neoangiogenesis, increased cell
proliferation, epithelial-to-mesenchymal transition (EMT)
and in acquired resistance to apoptosis (Huber et al. 2004;
Pikarsky et al. 2004; Julien et al. 2007; Pickering et al.
2007; Hafeez et al. 2008). NF-κB has been shown to pro-
mote breast cancer metastasis (Park et al. 2007), and ap-
pears to be a major regulator of prostate cancer cellsmetastasis to bone (Andela et al. 2003). Inhibition of NF-
κB activity in tumor cell lines increases their sensitivity to
chemotherapeutic drugs and radiation (Amit et al. 2003;
Tapia et al. 2007). Transcriptional activation of NF-κB
is effectively induced – independent of RasGTPase and
Raf-1 kinase - by members of Rho family of small
GTPases, that include RhoA, Cdc42 and Rac1 (Hodge
et al. 2003; Perona et al. 1997; Cammarano and Minden.
2001; Gnad et al. 2001). Conversely, blockage of Rho
pathways leads to suppression of NF-κB activity (Segain
et al. 2003). This relationship is becoming increasingly
important in deciphering regulatory underpinning of
one of the crucial elements of metabolic reprogramming
of cancer cell – it’s greatly elevated glutamine metabol-
ism - where, apparently, activation of the predominant
isoform of mitochondrial enzyme glutaminase is sub-
stantially influenced by concomitant RhoGTPase signal-
ing and NF-kB activation (Wilson et al. 2013).
Main function of DLC1 gene-encoded protein is in-
activation of Rho family of small GTPases (Durkin et al.
2007; Guan et al. 2008) by catalyzing the conversion of
active GTP-bound, into GDP-bound inactive form, and
thus blocking Rho pathway. The product of DLC1 gene
was shown to inactivate RhoA, RhoB, RhoC and to some
degree Cdc42, but not Rac (Zimonjic and Popescu
2012). DLC1 is frequently down regulated in prostate
cancer by either epigenetic modifications or deletion
(Guan et al. 2006) and its genomic under-representation
at chromosome 8p is associated with aggressive form of
prostate cancer (Matsuyama et al. 2001). Both C4-2-B2
and PC-3 cells are cancer cells and, as compared to
Figure 6 DLC1-mediated NF-κB suppression shows effects similar to sh(p65)NF-κB silencing or pharmacological down regulation of
NF-κB. (A) Western blot showing NF-κB (p65) knock down, D1, D2, D3 and D4 are different clones. Clone D4 was taken for study. Microphotographs
and/or quantitative valuation of Invasion Assay (B) Colony Formation (C) and Apoptosis Assay (D) of C4-2-B2 cells transduced with Lac Z or DLC1,
stably transfected with shNF-κB or treated with NF-κB inhibitor (Peptide inhibitor 150 μM). (E) Western blot analysis of NF-κB-induced genes in cell
extract from C4-2-B2 transduced and stably transfected with Ad-LacZ + sh-α-catenin, Ad-LacZ + sh-Neo, Ad-DLC1 + sh-α-catenin, Ad-DLC1 + sh-Neo,
or NF-κB peptide inhibitor (150 μM).
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RhoA. High level of total RhoA could affect Rho activity
only if RhoGAPs such as DLC1 - for which these cells
are negative - are absent. Otherwise, high total RhoA
would not have much effect on overall Rho activity.
Therefore, DLC1-mediated suppression of NF-κB activa-
tion could be a reflection of disruption of Rho signaling
pathway by one powerful RhoGAP, even more so given
that the results presented above demonstrated the de-
pendence of suppression on DLC1’s GAP activity. Yet,
the fact that re-expression of DLC1 alone was not suffi-
cient to affect NF-κB activation in α-catenin-negative PC3
cells, as opposed to α-catenin positive C4-2-B2 cells, points
to a more complex mechanism.
Loss of α-catenin in cancer cells results in increased
cell proliferation and resistance to apoptosis (Liu et al.
2007; Lien et al. 2006) whereas variations in availability
of either α-catenin or β-catenin were shown to influence
functional status of NF-κB (Deng et al., 2002; Kobielak
and Fuchs 2006; Solanas et al. 2008). Increased activationof NF-κB in C4-2-B2 and PC3 cells occurred in absence of
either DLC1 or α-catenin - or both of them - whereas only
the simultaneous expression of DLC1 and α-catenin was
effective in suppressing the NF-κB activity, thus portraying
DLC1’s GAP function as necessary, but not enough. How-
ever, just removal of calcium from chemical environment
was sufficient to cancel the joint DLC1-α-catenin suppres-
sion of NF-κB activation.
Calcium is instrumental for formation and integrity of
contact points between epithelial cells – adherens junc-
tions (AJ) - whose major molecular component is E-
cadherin, which maintains the connection to the actin
cytoskeleton through interaction with catenins (Wheelock
and Johnson 2003), and whose loss leads to up-regulation
of NF-κB activity (Kuphal et al. 2004). Conversely, stable
association of NF-κB with AJ’s proteins, primarily E-
cadherin, reduces its activity (Solanas et al. 2008; Kuphal
et al. 2004). Apparently, such immobilization of NF-κB is
enabled by β catenin, which acts as possible link between
p65 subunit of NF-κB and adherens junctions (Solanas
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stabilization through its interaction with E-cadherin via α-
catenin or by inducing E-cadherin expression (Tripathi
et al. 2012; Tripathi et al. 2013). One of the consequences
of increased AJ’s stability is down-regulation of RhoGT-
Pases (Asnaghi et al. 2010). As our aforementioned ana-
lysis of membrane and cytosolic cellular fractions showed,
DLC1 expression resulted in higher rate of association of
p65 subunit with the membrane, thus signaling increased
membrane localization of NF-κB, which coincided with its
reduced activity.
Inhibition of NF-κB activity in human prostate cancer
cells suppresses invasion, metastasis, and neoangiogen-
esis (Huang et al. 2001). Our results show that a major
NF-κB inhibitor, IκBα, whose IKK-mediated phosphoryl-
ation, ubiquitination and subsequent degradation takes
place in membrane ruffles (Boyer et al. 2004) is indeed,
localized in membrane ruffles of DLC-1 negative cells –
but is relocated into cytoplasm and, thus, rescued
from proteasomal degradation in cells with restored
DLC1 expression. Although IκBα physically interacts with
cytoskeleton-associated protein (Crepieux et al. 1997), we
do not have any evidence that DLC1 and IκBα proteins
directly interacts with each other. The fact that such a
process is contingent on presence of calcium, reaffirms
that the stability of AJs, resulting from intricate molecular
interactions between DLC1, α-catenin and E-cadherin,
appears to play a major role in regulating NF-κB activity.Conclusions
This study provides new evidences that tumor suppressor
gene DLC1, through its RhoGAP activity, affects the activa-
tion of NF-κB and, thus, modulates the complex signal
transduction pathways, which associate with inflammatory
response and cancer progression. It expands the known
DLC1 role and opens the prospect that DLC1 introduction,
or the inhibition of downstream pathways activated by
DLC1 deficiency, could sensitize chemotherapy-resistant
metastatic cancer to various pharmacological drugs.Methods
Cell lines and culture conditions
C4-2-B2 cell line was purchased from ViroMed, lab Inc
(Minneapolis, MN) and cultured in T-medium (Invitro-
gen, San Diego, CA) containing 10% FBS. PC-3 and
RWPE-1 cells lines were purchased from American Type
Culture Collection (Rockville, MD). PC-3 was cultured in
RPMI 1640 medium (Invitrogen, San Diego, CA) and
RWPE-1 was cultured in keratinocyte medium (Invitro-
gen, San Diego, CA) supplemented with Epithelial Growth
Factor (Invitrogen, San Diego, CA) and Bovine Pituitary
Extract (Invitrogen, San Diego, CA). All cell cultures were
grown in a humidified CO2 incubator at 37°C.Plasmids and transfections
For stable knock down of NF-κB (P65 subunit), four re-
spective SureSilencing shRNA plasmid vectors (KH01812P,
SA Biosciences, Frederick, MD), containing puromycin-
resistance gene were transfected using lipofectamine 2000
(Invitrogen, San Diego, CA). The media containing puro-
mycin was changed after 48 hours. For stable transfection
of α-catenin (KH00646N with neomycin) short hairpin
RNA (shRNA) and for DLC1 knock down (KH00438P
with Puromycin), SureSilencing shRNA plasmid vectors
(SA Biosciences, Frederick, MD) were transfected using
Lipofectamine 2000, and medium containing appropriate
antibiotics was changed after 48 h. Two weeks after trans-
fection, single colonies were picked up and expanded.
Stable clone for DLC1 R718E was made using G418 resist-
ance. An adenovirus encoding either DLC1 cDNA or
LacZ was prepared and transduced as previously de-
scribed (Guan et al., 2008). Adenovirus encoding α-catenin
was purchased from Vector Biolabs (Philadelphia, PA).
Immunoprecipitation and western blotting
Cells were transduced or transfected with various DLC1
constructs, α-catenin, and/or GFP-cadherin and lysed
with NP-40 lysis buffer (BioSource, Camarillo, CA) con-
taining Protease Inhibitor Cocktail (Sigma, St Lois, MO).
Centrifugation was done for 20 min at 12,000 × g to pro-
duce lysate for western blot or immunoprecipitation.
Anti-GFP antibody was added into precleared cell lysates
and incubated overnight at 4°C. Protein G-Sepharose
slurry (Zymed Inc., San Francisco, CA, USA) was added
and incubated for additional 2–3 hours. Immunoprecipi-
tates were washed and loaded on 4–12% SDS-PAGE gels
(Invitrogen, Carlsbad, CA), transferred to nitrocellulose
membranes (Invitrogen, Carlsbad, CA) and western blot-
ted with anti NF-κB antibody. Proteins were visualized
by horseradish peroxidase–conjugated secondary anti-
bodies and chemiluminescent HRP substrate (Millipore,
Billerica, MA). The following antibodies were used for
western blot: DLC1 monoclonal antibody (BD Transduc-
tion Laboratories, San Diego, CA), Anti-V5 (Invitrogen,
Carlsbad, CA), α-catenin and IκBα (Santa Cruz Biotech-
nology, Santa Cruz, CA), NF-κB (p65) and Phospho p65
antibody (Cell-signaling, Danvers, MA), and pIκBα and
GFP antibodies (Abcam, Cambridge, MA).
Immunofluorescence analysis
Cells were fixed in 4.0% paraformaldehyde for 20 min,
permeabilized with 0.2% Triton- X for 5 min, and then
subjected to staining with following antibodies: Goat
polyclonal DLC1, mouse monoclonal anti-E-cadherin, anti-
α-catenin, anti-NF-κB (p65) (Santa Cruz Biotechnology,
Santa Cruz, CA), and pNF-κB (Cell-signaling Danvers,
MA). For detection, anti-mouse Alexa Fluor 488, anti-goat
Alexa Fluor568, and anti-mouse Alexa Fluor 650
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cells were examined by a Zeiss LSM 510 NLO confocal
system (Carl Zeiss Inc, Thornwood, NY, USA) with an
inverted microscope (Axiovert 200 M) and a 30 mW argon
laser tuned to 488 nm, a 1 mW HeNe laser tuned to
543 nm and a 1 mW HeNe laser tuned to 633 nm. Images
were collected using a 63 × Plan-Apochromat 1.4 NA oil
immersion objective and a multi-track configuration in
Zeiss AIM software (v. 4.0) where the Alexa 488, Alexa
594, and Alexa 633 signals were sequentially collected
in separate PMTs with a BP 500–530 nm filter, BP
565–615 nm filter and BP 650–710 filter. Zoom was
set at 0.8 and images were 512 × 512 pixels with line
averaging of 4.
Preparation of sub cellular fractions
Subcellular fractions were prepared as described previ-
ously (Hodge et al. 2003). Briefly, cells were washed in
ice-cold PBS twice, to remove all media, then washed in
buffer A (100 mM sucrose, 20 mM HEPES pH 7.4,
1.5 Mm MgCl2, 1 mM EGTA, 1 mM EDTA and 1 mM
DTT) and resuspended in 500 μl of buffer B [buffer A
plus 5% Percoll, 0.01% digitonin, protease inhibitors
cocktails and 1 mM phenylmethylsulfonyl fluoride. After
20 min incubation on ice, the supernatant was centri-
fuged for 15 min at 15,000 × g to pellet mitochondria.
Then supernatant was centrifuged further at 100,000 × g
for 1 h. After centrifugation, supernatant and pellet were
designated as the cytosolic and membrane fractions,
respectively. Membrane pallet was washed twice with
Buffer A and then dissolved in appropriate amount of
Buffer A supplemented with 1.0% Triton-X.
RhoA activation assay
RhoA activation assay was done according to manufac-
turer’s (Cell Biolabs, San Diego, CA) instructions. Briefly,
cells were lysed in 1X lysis buffer supplemented with
protease inhibitors cocktail (Sigma-Aldrich, St. Louis,
MO) and the lysate was centrifuged at 4°C for 10 min at
12,000 × g. An aliquot of lysate was analyzed for total
protein content and total RhoA, and the rest of the ly-
sates was used for the Rhotekin assay. Rhotekin beads
were added to cell lysates, incubated for 4 hours, and
washed thoroughly 3–4 times in washing buffer. Active
Rho protein bound to beads was separated in 4-12%
acrylamide gels and immunoblotted with anti-RhoA
antibody (Abcam, Cambridge, MA).
Ubiquitination assay
C42-B2 cells were transduced with Ad-LacZ/Ad-DLC1
or transfected with R718E DLC1. Cells were treated for
8 hours with 10 μM of proteasome inhibitor MG132(Sigma-Aldrich, St. Louis, MO), lysed and the lysates
were precleared. Ten micrograms of IκBα antibody were
added to 500 μg of cell lysate and incubated in cold
room for 4 hours. Then, protein G sepharose was added
and incubated for further 2 hours. After centrifugation
at 5000 g for 5 min, pellets were washed 3–4 times with
lysis buffer, proteins were boiled in loading buffer and sub-
jected to immunoblotting analyses with anti-ubiquitin
antibody.Colony formation in soft agar
Soft agar assay was performed using Cell Transform-
ation Detection Assay kit (Chemicon, Temecula, CA).
Cells were suspended in 0.35% low melting agarose at
2 × 104 cells per well, plated on a layer of 0.8% agarose/
T-medium (5%) in six-well culture plates and cultured at
37°C with 5% CO2. After 4 weeks, colonies were stained
and imaged.Apoptosis analysis
Cells were harvested by trypsinization and washed twice
with ice-cold PBS. Samples were centrifuged for 3 min
at 200 × g, rinsed with PBS, and re-suspended in FITC-
labeled annexinV/propidium iodide (PI) according to the
manufacturers instructions (Chemicon, Temecula, CA).
Apoptotic cells were analyzed by flow cytometry on a
FACScan Instrument (Becton Dickinson, San Jose, CA).Invasion assay
Cell invasion assays were performed using 8 μm pore-
size chambers (Becton Dickinson, Franklin Lakes, NJ).
Cells were transduced with Ad-DLC1 or Ad-LacZ or sta-
bly transfected with ShRNA of NF-κB or treated with
150 μM of peptide inhibitor of NF-κB (IMGENEX, San
Diego, CA) and 1 × 106 cells/well were plated on EC-
Matrix coated cell culture inserts. After incubation, the
non-invading cells were removed from the interior of
the inserts using a cotton-tipped swab. Invaded cells
were stained with DiffQuick and counted (Dade Behring,
Newark, DE, USA).Luciferase reporter assay
Ad-LacZ or DLC1 transduced C4-2-B2, and α-catenin
transduced PC-3 cells were transfected with NFκB re-
porter plasmid, or negative and positive control plasmid
(SA Biosciences, Frederick, MD) and incubated for
48 hours. Cells were washed with PBS (pH-7.6) and
lysed with reporter lysis buffer (Promega, Madison, WI).
After centrifugation for 10 mins, supernatant was collected.
Luciferase activity was measured using the Dual-Luciferase
Reporter Assay System (Promega, Madison, WI).
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Statistical analysis of quantitative data was carried out
when appropriate, and levels of statistical significance
were assessed using two-tailed paired Student’s T- test.
All numerical values represent means ± S.E.M from three
independent experiments.
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